[go: up one dir, main page]

NO306061B1 - Pyridaziner som inhibitorer av interleukin-1<beta>-omdannende enzym, farmasöytisk preparat inneholdende slike forbindelser og deres anvendelse - Google Patents

Pyridaziner som inhibitorer av interleukin-1<beta>-omdannende enzym, farmasöytisk preparat inneholdende slike forbindelser og deres anvendelse

Info

Publication number
NO306061B1
NO306061B1 NO942133A NO942133A NO306061B1 NO 306061 B1 NO306061 B1 NO 306061B1 NO 942133 A NO942133 A NO 942133A NO 942133 A NO942133 A NO 942133A NO 306061 B1 NO306061 B1 NO 306061B1
Authority
NO
Norway
Prior art keywords
alkyl
compounds
aryl
chr5
beta
Prior art date
Application number
NO942133A
Other languages
English (en)
Norwegian (no)
Other versions
NO942133L (no
NO942133D0 (no
Inventor
Roland E Dolle
Stanley J Schmidt
Denton W Hoyer
Tina M Ross
James M Rinker
Mark A Ator
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO942133D0 publication Critical patent/NO942133D0/no
Publication of NO942133L publication Critical patent/NO942133L/no
Publication of NO306061B1 publication Critical patent/NO306061B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO942133A 1993-06-08 1994-06-08 Pyridaziner som inhibitorer av interleukin-1<beta>-omdannende enzym, farmasöytisk preparat inneholdende slike forbindelser og deres anvendelse NO306061B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7391493A 1993-06-08 1993-06-08

Publications (3)

Publication Number Publication Date
NO942133D0 NO942133D0 (no) 1994-06-08
NO942133L NO942133L (no) 1994-12-09
NO306061B1 true NO306061B1 (no) 1999-09-13

Family

ID=22116553

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942133A NO306061B1 (no) 1993-06-08 1994-06-08 Pyridaziner som inhibitorer av interleukin-1<beta>-omdannende enzym, farmasöytisk preparat inneholdende slike forbindelser og deres anvendelse

Country Status (18)

Country Link
US (3) US6121266A (da)
EP (1) EP0628550B1 (da)
JP (1) JPH0769894A (da)
KR (1) KR950000673A (da)
AT (1) ATE163412T1 (da)
AU (1) AU693786B2 (da)
CA (1) CA2125359A1 (da)
CZ (1) CZ140194A3 (da)
DE (1) DE69408598T2 (da)
DK (1) DK0628550T3 (da)
ES (1) ES2114654T3 (da)
FI (1) FI942693A7 (da)
HU (1) HUT67413A (da)
IL (1) IL109918A0 (da)
NO (1) NO306061B1 (da)
NZ (1) NZ260698A (da)
RU (1) RU94019984A (da)
SK (1) SK69794A3 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DK0628550T3 (da) 1993-06-08 1998-09-28 Vertex Pharma Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6162828A (en) * 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
GB9715640D0 (en) * 1997-07-24 1997-10-01 M J Highway Technology Limited Road repair material
AU738595B2 (en) * 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
EP1604984A1 (en) 2003-03-18 2005-12-14 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
CA2547518A1 (en) * 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
JP4989456B2 (ja) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
CN102362867A (zh) * 2004-05-15 2012-02-29 沃泰克斯药物股份有限公司 使用ice抑制剂治疗癫痫发作
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP2592075B1 (en) 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
EP2063894B1 (en) 2006-04-28 2019-08-28 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
KR102419136B1 (ko) 2017-06-15 2022-07-08 삼성전자주식회사 다채널 특징맵을 이용하는 영상 처리 장치 및 방법
CN112689629B (zh) * 2018-07-09 2024-04-23 利伯研究所公司 用于抑制Nav1.8的哒嗪化合物
US12234221B2 (en) 2018-07-09 2025-02-25 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NAV1.8

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603244A (en) * 1977-05-20 1981-11-18 Max Planck Gesellschaft Medicaments for the suppression of pathological processes
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
US4590194A (en) * 1981-10-05 1986-05-20 Sterling Drug Inc. 3-[methyl or dimethyl)amino]-6-(pyridinyl)pyridazines and their cardiotonic use
AU601145B2 (en) * 1985-03-01 1990-09-06 Duphar International Research B.V. Benzoyl urea derivatives having anti-tumor activity
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
CA2071674C (en) * 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
DK0628550T3 (da) 1993-06-08 1998-09-28 Vertex Pharma Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer

Also Published As

Publication number Publication date
SK69794A3 (en) 1995-02-08
FI942693L (fi) 1994-12-09
IL109918A0 (en) 1994-10-07
FI942693A7 (fi) 1994-12-09
DK0628550T3 (da) 1998-09-28
NO942133L (no) 1994-12-09
ATE163412T1 (de) 1998-03-15
US20040110725A1 (en) 2004-06-10
AU693786B2 (en) 1998-07-09
EP0628550B1 (en) 1998-02-25
JPH0769894A (ja) 1995-03-14
CA2125359A1 (en) 1994-12-09
NO942133D0 (no) 1994-06-08
US6121266A (en) 2000-09-19
HUT67413A (en) 1995-04-28
EP0628550A2 (en) 1994-12-14
NZ260698A (en) 1996-09-25
AU6455694A (en) 1994-12-15
CZ140194A3 (en) 1995-01-18
RU94019984A (ru) 1997-04-10
DE69408598T2 (de) 1998-09-17
HU9401714D0 (en) 1994-09-28
KR950000673A (ko) 1995-01-03
ES2114654T3 (es) 1998-06-01
US6995261B2 (en) 2006-02-07
EP0628550A3 (en) 1995-01-18
FI942693A0 (fi) 1994-06-08
US6624166B1 (en) 2003-09-23
DE69408598D1 (de) 1998-04-02

Similar Documents

Publication Publication Date Title
NO306061B1 (no) Pyridaziner som inhibitorer av interleukin-1&lt;beta&gt;-omdannende enzym, farmasöytisk preparat inneholdende slike forbindelser og deres anvendelse
DE69332860D1 (de) Bicyklische fibrinogen antagoniste
EP0322738A3 (en) Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells
DK43683A (da) Aromatiske forbindelser med antihistamin-aktivitet, fremgangsmaade til deres fremstilling samt deres anvendelse
TW375612B (en) 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
FI834791A0 (fi) Foerfarande foer framstaellning av pyrinderivat
WO1986007059A3 (en) Oxodiazine compounds
DK164159C (da) Oeoeoe(3-pyridinyl)methylenaaaminoaaoxyaaalkansyrederivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
AU556474B2 (en) Benzhydryl piperazine derivatives
DK159650C (da) 1,1-diphenylpropan-1-ol-derivater, fremgangsmaade til fremstilling heraf, farmaceutiske praeparater indeholdende disse, samt fremgangsmaade til fremstilling af disse farmaceutiske praeparater
DK624086A (da) 6h-isoxazolo(3,4-d)pyrazolo(3,4-b)pyridiner eller farmaceutisk acceptable syreadditionssalte deraf, deres fremstilling og anvendelse som anxiolytika
MY101815A (en) Heterocyclic oxophthalazinyl acetic acids.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees